Prespecified FLOW secondary analysis testing whether semaglutide’s kidney and cardiovascular benefit differs by baseline SGLT2 inhibitor use in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Pre-specified FLOW subgroup analysis of semaglutide for kidney outcomes in type 2 diabetes and chronic kidney disease, by baseline SGLT2 inhibitor use. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds once-weekly semaglutide 2.4 mg modestly lowered a composite kidney endpoint versus placebo in adults with overweight or obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
Prespecified pooled analysis of the STEP-HFpEF program: once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide 1.0 mg lowered the risk of major kidney disease events and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows once-weekly semaglutide 2.4 mg lowered NT-proBNP and improved symptoms in obesity-related HFpEF. PICO summary and expert commentary.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…